Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

Medicine & Life Sciences

• Thrombopoietin 100%
• Thrombocytopenia 69%
• Liver Diseases 62%
• Chronic Disease 54%
• Platelet Count 53%
• Hemorrhage 47%
• lusutrombopag 39%
• 1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid 38%
• eltrombopag 30%
• Drug Approval 23%
• Hemostatics 19%
• United States Food and Drug Administration 18%
• Placebos 12%
• Randomized Controlled Trials 12%
• Liver 9%